Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Operating Leases: 2021-2025

Historic Operating Leases for Roivant Sciences (ROIV) over the last 5 years, with Sep 2025 value amounting to $89.8 million.

  • Roivant Sciences' Operating Leases rose 108.02% to $89.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.8 million, marking a year-over-year increase of 108.02%. This contributed to the annual value of $90.3 million for FY2025, which is 100.64% up from last year.
  • Roivant Sciences' Operating Leases amounted to $89.8 million in Q3 2025, which was down 0.50% from $90.3 million recorded in Q2 2025.
  • Roivant Sciences' Operating Leases' 5-year high stood at $90.5 million during Q4 2024, with a 5-year trough of $43.2 million in Q3 2024.
  • For the 3-year period, Roivant Sciences' Operating Leases averaged around $63.3 million, with its median value being $51.8 million (2023).
  • In the last 5 years, Roivant Sciences' Operating Leases fell by 17.06% in 2022 and then skyrocketed by 108.02% in 2025.
  • Over the past 5 years, Roivant Sciences' Operating Leases (Quarterly) stood at $62.1 million in 2021, then declined by 11.54% to $54.9 million in 2022, then declined by 14.32% to $47.1 million in 2023, then surged by 92.27% to $90.5 million in 2024, then spiked by 108.02% to $89.8 million in 2025.
  • Its Operating Leases stands at $89.8 million for Q3 2025, versus $90.3 million for Q2 2025 and $90.3 million for Q1 2025.